L Rhoda Molife

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 339 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +16

Secondary mutations in <i><scp>BRCA2</scp></i> associated with clinical resistance to a <scp>PARP</scp> inhibitor

Louise J. Barber, Shahneen Sandhu, Lina Chen et al. · The Journal of Pathology · 2012 · 335 citations

Medicine, Cancer Biology, Oncology +17

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel et al. · Clinical Cancer Research · 2007 · 268 citations

Pharmacy, Oncology, Pharmacology +15

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

Géraldine Perkins, Timothy A. Yap, Lorna Pope et al. · PLoS ONE · 2012 · 146 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?

Sophie Postel‐Vinay, Carlos Gomez‐Roca, L Rhoda Molife et al. · Journal of Clinical Oncology · 2011 · 138 citations

Pharmacy, Pharmacology, Cancer Drug Toxicity Management +16